Operating Segments (Tables)

3 Months Ended

Mar. 31, 2015

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended March 31,
	2015			2014
Contract/Grant Revenue
Vaccines/BioDefense	$	802,314		$	877,045
BioTherapeutics		13,972			33,552
Total	$	816,286		$	910,597
Income/(Loss) from Operations
Vaccines/BioDefense	$	84,681		$	139,404
BioTherapeutics		(764,876	)		(1,035,591	)
Corporate		(878,072	)		(693,722	)
Total	$	(1,558,267	)	$	(1,589,909	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,786		$	9,935
BioTherapeutics		48,374			49,939
Corporate		1,766			2,213
Total	$	59,926		$	62,087
Interest Income
Corporate	$	561		$	291
Share-Based Compensation
Vaccines/BioDefense	$	24,592		$	10,450
BioTherapeutics		29,256			76,121
Corporate		88,177			90,091
Total	$	142,025		$	176,662

	As of March 31, 2015		As of  December 31,  2014
Identifiable Assets
Vaccines/BioDefense	$	568,565	$	1,025,220
BioTherapeutics		161,355		204,308
Corporate		5,172,737		5,724,720
Total	$	5,902,657	$	6,954,248